Healthcare ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Research and Development AI in Healthcare Obesity Treatments Market Trends GLP-1 Medications Innovation ALS Treatment Global Market Shares Antiviral Drugs Pricing Policies FDA Approval Investigational Drugs Long-Acting Injectables Compounding Pharmacy Diabetes Treatment Biologics Market Competition Cancer Medicines Antibiotics Oncology Drugs Market Strategy Regulatory Approval Cancer Drugs Pricing Strategies Biopharmaceuticals Immunological Treatments Covid-19 Vaccines Weight-loss Medications Huntington's Disease Research Funding Efficacy Studies Market Access Cancer Treatments Cancer Therapies Monoclonal Antibodies Mental Health Treatments Weight Loss Medications Sustainability Obesity Treatment Regulatory Compliance Clinical Efficacy Weight Loss Drugs Weight Management Drugs

Investor Law Firms Rally uniQure Case as April 13 Lead-Plaintiff Deadline Nears

The filings set an April 13, 2026 deadline for investors to seek lead-plaintiff status over alleged misstatements tied to AMT-130.

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Teva’s Olanzapine LAI Shows No PDSS in Phase 3 SOLARIS Long-Term Data Presented at Psych Congress

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030